| Literature DB >> 35573874 |
Mansi Shah1, Nrupesh Patel1, Nagja Tripathi2, Vivek K Vyas3.
Abstract
Capillary electrophoresis (CE) is widely used for the impurity profiling of drugs that contain stereochemical centers in their structures, analysis of biomolecules, and characterization of biopharmaceuticals. Currently, CE is the method of choice for the analysis of foodstuffs and the determination of adulterants. This article discusses the general theory and instrumentation of CE as well as the classification of various CE techniques. It also presents an overview of research on the applications of different CE techniques in the impurity profiling of drugs in the past decade. The review briefly presents a comparison between CE and liquid chromatography methods and highlights the strengths of CE using drug compounds as examples. This review will help scientists, fellow researchers, and students to understand the applications of CE techniques in the impurity profiling of drugs.Entities:
Keywords: Capillary electrophoresis; Drugs; Impurities; Impurity profiling
Year: 2021 PMID: 35573874 PMCID: PMC9073252 DOI: 10.1016/j.jpha.2021.06.009
Source DB: PubMed Journal: J Pharm Anal ISSN: 2214-0883
Fig. 1Cross section of capillary in capillary electrophoresis (CE).
Fig. 2Movement of a conductive medium through a capillary.
Fig. 3Instrumentation of CE.
Fig. 4Classification of various CE techniques under the continuous and discontinuous systems. CITP: capillary isotachophoresis; CIEF: capillary isoelectric focusing; MEKC: micellar electrokinetic chromatography; CZE: capillary zone electrophoresis; CGE: capillary gel electrophoresis.
Fig. 5Capillary zone electrophoresis (CZE). EOF: electro-osmotic flow.
Fig. 6Micellar electrokinetic capillary electrophoresis (MEKC).
Year-wise details of past reviews on CE along with studied analytes and field of study.
| Title of review | Studied analytes | Field of study | Year | Refs. |
|---|---|---|---|---|
| Capillary electrophoresis based immunoassays: a critical review | Free antibody, free antigen, antigen-antibody complex | Immunoassay in research and clinical diagnostics | 1997 | [ |
| Highlight. capillary electrophoresis coupled to electrochemical detection: a review of recent advances | Carbohydrates, amines, peptides, sulphur disulfides, inorganic ions, purine-related compounds | Coupled electrochemical detection and CE (CEEC) | 1998 | [ |
| Capillary electrophoresis as a versatile tool for the bioanalysis of drugs—a review | Analysis of drugs in biological matrices | Bioanalytical applications of CE | 1999 | [ |
| Overview of capillary electrophoresis and capillary electrochromatography | DNA, carbohydrates, proteins, metal ions, pharmaceuticals, enantiomeric species | Clinical, biomedical and forensic applications of CE and microchip CE | 1999 | [ |
| Capillary electrophoresis for forensic drug analysis: a review | Drug seizures and non-biological samples | Forensic drug analysis | 2005 | [ |
| Capillary electrophoresis in pharmaceutical analysis (a review) | Drug impurities, parent drugs, vitamins, enantioselective isomers | Detection of anions and cations in stoichiometric analysis | 2006 | [ |
| Capillary electrophoresis-based methods for the determination of lipids: a review | Fatty acid, glycerophospholipids, triglycerides, sterols | Determination of lipids | 2008 | [ |
| Recent advances of capillary electrophoresis in pharmaceutical analysis | Active pharmaceutical ingredients (API), impurities, chiral compounds, biological fluids | Application of CE in pharmaceutical analysis | 2010 | [ |
| Coupling isotachophoresis and capillary electrophoresis: a review and comparison of methods | Drug components | Coupled isotachophoresis and capillary electrophoresis (tITP-CE) | 2013 | [ |
| The application of capillary electrophoresis techniques in toxicological analysis | Toxicological products present in the drug components and biological matrices | Applications of different types of CE in toxicological analysis | 2014 | [ |
| Capillary electrophoresis: trends and recent advances | Nanoparticles, nucleic acid, viruses, metabolites, amino acids, carbohydrates, biopharmaceuticals, proteins | New developments in the broad field of CE | 2018 | [ |
| Recent advances in capillary electrophoresis-mass spectrometry: instrumentation, methodology and applications | Proteins, peptides, metabolites, API, biological fluids | Applications of hyphenated CE-MS | 2019 | [ |
| Recent developments and applications of capillary and microchip electrophoresis in proteomics and peptidomics | Enzymes, hormones, antibodies, transporters | Microchip electro-separation methods for proteomics and peptidomes | 2019 | [ |
| Recent developments of capillary electrophoresis in seawater analysis | Phosphates, iodide, bromate, fluorides, peptides and inorganic ions | Analysis of sea water | 2019 | [ |
| Advances in capillary electrophoresis for the life sciences | Biopharmaceutical molecules | Role of CE in the development of life sciences | 2019 | [ |
Fig. 7Chemical structures of drugs and their related substances/impurities identified/searched using CZE.
Review of capillary zone electrophoresis (CZE) method with the details of background electrolyte conditions for impurity profiling of drugs.
| Name of Drug | Background electrolyte | Name of impurities/related substances | Limit of detection (%) | Refs. | |||
|---|---|---|---|---|---|---|---|
| Analyte | Voltage (kV) | Temperature (°C) | Wave length (nm) | ||||
| Primaquine | a) 50 mM phosphoric acid | 15 | 25 | 254 | a) Quinocide | – | [ |
| Kanamycin | a) 40 mM | 30 | 25 | 234 | a) Paromamine | 0.10 | [ |
| Amikacin | a) 20 mM MES | 30 | 25 | 234 | a) Kanamycin | 1.4 | [ |
| Metformin | a) 35 mM Britton-Robinson buffer | 30 | 26 | 234 | a) Melamine-1,3,5 triazine-2,4,6 triamine | – | [ |
| Levosulpride | a) 9–12 mM sulfated-β-CD | 12–14 | 16 | 288 | a) Levosulpride related impurities | 0.12 | [ |
| Ambrisarten | a) 100 mM borate buffer (pH 9.20) | 30 | 22 | – | a) Diphenylmethon 4,6-dimethyl-2-methyl-sulfonyl-pyrimidine | – | [ |
| Tipranavir | a) 50 mM sodium borate | 28 | 25 | 240 | a) Tipranavir related impurities | – | [ |
| Zofenopril | a) 100 mM sodium tetraborate decahydrate | 17 | 25 | 225 | a) Chlorothiazide | 0.02 | [ |
| Cinacalcet | a) 150 mM phosphate buffer | 26 | 18 | 220 | – | [ | |
CTAB: N-cetyltrimethyl ammonium bromide; MES: morpholine ethyl sulfonate; β-CD: β-cyclodextrin; HPγCyD: (2-carboxyethyl)-β-cyclodextrin and (2-hydroxypropyl)-γ-cyclodextrin.
Fig. 8Chemical structures of drugs and their related substances/impurities identified/searched using microemulsion electrokinetic chromatography (MEEKC).
Review of microemulsion electrokinetic chromatography (MEEKC) method with the details of background electrolyte conditions for impurity profiling of drugs.
| Name of Drug | Background electrolyte | Name of impurities/related substances | Limit of detection (%) | Refs. | |||
|---|---|---|---|---|---|---|---|
| Analyte | Voltage (kV) | Temperature (°C) | Wave length (nm) | ||||
| Clemastine | a) 10 mM borate buffer (pH 9.2) | 17 | 20 | 195 | a) 2-(2-(1-(4-chlorophenyl-1-pphenylethoxy)ethyl)-1-methylpyrrolidine1-oxide | 0.04 | [ |
| Dexamphetamine | a) 1.5% SDS | 14 | 20 | 195 | Dexamphetamine related impurities | 0.05 | [ |
| Ramipril | a) 90 mM phosphate (pH 2.5) | 26 | 17 | 210 | a) Ramipril methyl ester | <0.01 | [ |
| Almotriptan | a) 30 mM borate buffer (pH 9.4) | 27 | 24 | 227 | a) Almotriptan- | <0.01 | [ |
| Fluoroquinolones | a) 125 mM NaH2PO4, pH of 2.75 | 28 | 25 | 295 | a) Norfloxacin | – | [ |
Fig. 9Chemical structures of drugs and their related substances/impurities identified/searched using MEKC.
Review of micellar electrokinetic chromatography (MEKC) method with the details of background electrolyte conditions for impurity profiling of drugs.
| Name of drug | Background electrolyte | Name of impurities/related substances | Limit of detection (%) | Refs. | |||
|---|---|---|---|---|---|---|---|
| Analyte | Voltage (kV) | Temperature (°C) | Wave length (nm) | ||||
| Budesonide | a) 65 mM CHOL and 10 mM MAPS | 16 | 21 | 245 | a) 16-α-hydroxyprednisole | 0.60 | [ |
| Ertapenem | a) 60 mM of NaH2PO4 and 20 mM H3BO3 buffer | 18 | – | 214 | a) Pro-MABA | [ | |
| Valacyclovir | a) 20 mM citric acid | 25 | 28 | 254 | a) Acyclovir | 0.02 | [ |
| Gliclazide | a) 40 mM citrate (pH 6.7) | 20 | 25 | 225 | a) Gliclazide impurity B | 0.12 | [ |
| Palonosetron | a) 30 mM sodium cholate | 25 | 25 | 214 | Palonosetron related impurity | <0.01 | [ |
| Zolmitriptan | 138 mM phosphate buffer (pH 2.74) | 30 | 25 | 227 | a) Decarbonyl zolmitriptan | – | [ |
| Goserelin | a) 6-Amino caproic acid (pH 4.2) | 10 | 20 | 220 | Goserelin related peptides | [ | |
CHOL: sodium cholate; MAPS: 3-(N,N-dimethylmyristylammonio)propanesulfonate; SDS: sodium dodecyl sulphate; CTAB: N-cetyltrimethyl ammonium bromide; CD: cyclodextrin; Pro-MABA: proline amide of m-aminobenzoic acid.
Fig. 10Chemical structures of flurbiprofen and flufenamic acid identified using non-aqueous capillary electrophoresis.
Fig. 11Chemical structures of zopiclone and its impurities identified using electrokinetic chromatography.
Review of CE methods for Pharmacopeial monographs with the details of monograph number, background electrolyte conditions and name of impurities/related substances.
| Name of Pharmacopoeial monograph | Monograph number | Method of analysis | Voltage (kV) | Temp. (°C) | Wave length (nm) | Name of impurity/related substances | Refs. |
|---|---|---|---|---|---|---|---|
| Aprotinin and aprotinin concentrated solution | Ph. Eur 0579, 0580 | Capillary zone electrophoresis | ±12 | 25 | 214 | Aprotinin impurity | [ |
| Erythropoietin concentrated solution | Ph. Eur 1316 | Capillary zone electrophoresis | ±16 | 35 | 214 | 1-8 Isomeric forms | [ |
| Amlotriptan malate | USP | Micellar electrokinetic electrophoresis | ±15 | 15 | 214 | Almotriptan | [ |
| Betadex sulfobutyl ether sodium | USP | Gel capillary electrophoresis | ±30 | 25 | 205 | Impurity 1-10 | [ |
| Erythropoietin concentrated solution | USP | Capillary zone electrophoresis | ±20 | 35 | 214 | Isoforms of erythropoietin | [ |
| Glutathione | Ph. Eur 1670, B.P. | High performance capillary electrophoresis | 20 | 25 | 200 | [ | |
| Levocabastine hydrochloride | Ph. Eur 1484, B.P. | Capillary zone electrophoresis | – | 50 | 214 | Related impurities | [ |
| Ropivacaine | Ph. Eur 2335, B.P. | Capillary zone electrophoresis | – | 30 | 206 | Enantiomeric impurities | [ |
| Somatropin for injection | Ph. Eur 2370, B.P. | Capillary zone electrophoresis | 20 | 30 | 200 | Charged variants | [ |
| Trypsin inhibitor | USP | Capillary zone electrophoresis | ±12 | 25 | 214 | Related impurities | [ |
Comparison of CE with LC.
| Parameters | Capillary electrophoresis | Liquid chromatography |
|---|---|---|
| Analysis time | Fast (1–20 min) | Moderate (10–60min) |
| Cost | Low | Moderate |
| Sample quantity | Very low | Moderate |
| Solvent consumption (volume) | Less (1–100 nL) | Moderate (1–100 μL) |
| Instrumentation | Simple to operate | More complex to operate |
| Graph shape | Narrow peak for better resolution | Pumped parabolic flow |
Comparison of LC and CE with examples of impurity profiling of drugs.
| Name of drug | Mobile phase | Wavelength (nm) | Number of impurities/related substances identified | Run time (min) | Refs. | ||||
|---|---|---|---|---|---|---|---|---|---|
| LC | CE | LC | CE | LC | CE | LC | CE | ||
| Primaquine | Aqueous trifluroacetic acid and acetonitrile (75:25, | 50 M phosphoric acid, 1 M Tris solution, 0.2 μm cellulose nitrate, buffer | 265 | 254 | 2 | 1 | 34 | 5 | [ |
| Kanamycin | 0.1 M disodium tetraborate (pH 9.0 using dilute phosphoric acid) | 40 mM | 205 | 234 | 5 | 6 | 17 | 5 | [ |
| Metformin | Buffer and acetonitrile (94:06, | 35 mM Britton-Robinson buffer, 15 mM CM-β-CD | 218 | 234 | 1 | 5 | 80 | 4 | [ |
| Zofenopril | Aqueous ammonium acetate buffer (20 mM) and acetonitrile (50:50, | 100 mM sodium tetraborate decahydrate, pH 9.15, | 247 | 225 | 1 | 3 | 15 | 5 | [ |
| Cinacalcet | Aqueous ammonium acetate buffer (20 mM) and acetonitrile (50:50, | 150 mM phosphate buffer, 3.1 mM HPγCyD, 2% methanol | 247 | 220 | 5 | 4 | 15 | 5 | [ |
| Budesonide | Ethanol–acetonitrile–phosphate buffer (pH 3.4; 25.6 mM) (2:30:68, | 65 mM CHOL and 10 mM MAPS | 240 | 245 | 1 | 4 | 20 | 18 | [ |
| Ertapenem | Ammonium formate buffer (pH 8.0), water and acetonitrile (40:60:01, | 60 mM of NaH2PO4 and 20 mM H3BO3 buffer, pH 6, 80 mM SDS | 225 | 214 | 27 | 9 | 10 | 10 | [ |
| Gliclazide | Acetonitrile and sodium dihydrogen phosphate solution (0.02 M) | 40 mM citrate (pH 6.7), 10 mM NaH2PO4 buffer (pH 7.0–9.0), 10–50 mM SDS | 235 | 225 | 7 | 2 | 30 | 6 | [ |
| Palonosetron | Buffer solution: acetonitrile (50:50, | 30 mM SC, 30 mM sodium tetraborate buffer of pH 9.20 | 210 | 214 | 3 | 4 | 40 | 20 | [ |
| Zolmitriptan | Phosphate buffer of pH 9.85: methanol: acetonitrile (70:20:10, | 138 mM phosphate buffer (pH 2.74) | 225 | 227 | 3 | 5 | 30 | 4.5 | [ |
| Zolmitriptan | 0.02 M ammonium formate containing 0.1% | 138 mM phosphate buffer (pH 2.74) | 225 | 227 | 2 | 5 | 60 | 4.5 | [ |
| Valacyclovir | 0.1% ammonium acetate in water and acetonitrile (95:5, | 20 mM citric acid, 1 M Tris solution (pH 2.75), 125 mM SDS | 254 | 254 | 3 | 3 | 10 | 5 | [ |
| Valacyclovir | Acetonitrile: methanol (90:10, | 20 M citric acid, 1 M Tris solution (pH 2.75), 125 mM SDS | 254 | 254 | 2 | 3 | 40 | 5 | [ |